Semaglutide can make appetite quieter. The stomach is often the first part of the body to notice.
The most common semaglutide side effects are nausea, diarrhea, vomiting, constipation, and stomach pain—mostly during dose escalation.
That is the useful answer. The side-effect list is mostly digestive, the timing is predictable, and the current FDA label gives clear numbers.
See Certiva Semaglutide specifications →
What should you know first?
Most reported effects involve digestion, but persistent or severe symptoms deserve attention.
Most common
Nausea and diarrhea
These were the two most frequently reported reactions in adult Wegovy injection trials.
Most likely time
While the dose increases
The label says digestive reactions were reported most often during dose escalation.
Call for help
Severe or lasting symptoms
Persistent pain, vomiting, dehydration, or allergic-reaction signs need medical attention.
Semaglutide side effects at a glance
The current U.S. Wegovy injection label includes the following adult weight-management trial results:
| Side effect | Wegovy injection 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 25% | 6% |
| Constipation | 24% | 11% |
| Stomach pain | 20% | 10% |
| Headache | 14% | 10% |
| Fatigue | 11% | 5% |
| Indigestion | 9% | 3% |
These percentages describe adults in clinical trials of the finished Wegovy medicine. They are not a prediction for one individual and do not describe a Certiva laboratory research vial.
See the current Wegovy prescribing information on DailyMed.
Why does semaglutide affect the stomach?
Semaglutide activates the GLP-1 receptor.
That signal helps with appetite, fullness, and the body’s response to food. It also slows gastric emptying—the movement of food from the stomach into the small intestine.
Slower movement can help fullness last longer. It can also explain why the digestive system produces most of the complaints:
- nausea;
- feeling overly full;
- belching or indigestion;
- constipation;
- diarrhea; or
- vomiting.
The appetite effect and the stomach effect are connected to the same GLP-1 story. That is why digestive symptoms are so familiar across this medicine category.
For the simple mechanism, read how semaglutide and GLP-1 work.
When are side effects most likely?
The current label says digestive reactions were most frequently reported during dose escalation—the period when a prescriber gradually increases the dose.
This is also why a finished prescription medicine has a scheduled escalation plan. The plan belongs to the approved product and the individual patient; it should be followed with the prescribing healthcare professional.
In the adult weight-management trials:
- 73% of Wegovy injection participants reported a gastrointestinal reaction;
- 47% of placebo participants reported one;
- severe gastrointestinal reactions occurred in 4.1% and 0.9%, respectively;
- 4.3% of Wegovy injection participants permanently stopped because of a gastrointestinal reaction, compared with 0.7% receiving placebo.
The other side of those numbers is important: most participants did not stop the medicine because of digestive effects.
Is nausea the most common semaglutide side effect?
Yes. Nausea led the adult Wegovy injection trial table at 44%.
Diarrhea followed at 30%. Vomiting and constipation were each reported by about one quarter of participants.
Nausea does not automatically mean something dangerous is happening. But nausea that is severe, does not improve, prevents fluids from staying down, or comes with strong pain needs professional advice.
The practical consumer rule is simple:
Common does not mean “ignore it.” It means know what is expected and notice when the pattern becomes severe or persistent.
Does semaglutide cause constipation?
Constipation is a common reported effect.
In the adult Wegovy injection trial table, it appeared in 24% of participants receiving semaglutide and 11% receiving placebo.
The slowed movement of food through the digestive system helps explain the pattern. Constipation can also feel more noticeable when appetite and food intake drop.
People using an approved semaglutide medicine should ask their healthcare professional about symptoms that are painful, persistent, or accompanied by significant swelling or vomiting.
Does semaglutide cause hair loss?
Hair loss appeared in the current adult trial table:
- 3% with Wegovy injection;
- 1% with placebo.
The label reports the observation. It does not say that every person will experience it.
Hair growth moves in slow cycles, and rapid body changes can affect those cycles. A healthcare professional can help look at the full picture, including nutrition, other medicines, illness, hormones, and the timing of weight change.
What serious warning signs matter?
Most side effects are digestive and manageable. A smaller set of symptoms needs faster medical attention.
Contact a healthcare professional promptly for:
- severe stomach problems or repeated vomiting;
- signs of dehydration, such as very dark urine, faintness, or trouble keeping fluids down;
- new or major vision changes;
- pain in the upper stomach with fever or yellow skin or eyes;
- a serious allergic reaction, including swelling or trouble breathing; or
- persistent severe stomach pain, especially pain that may move toward the back.
The finished medicine’s label also includes important warnings and contraindications, including a boxed warning about thyroid C-cell tumors observed in rodents. A licensed healthcare professional should apply the current label to an individual’s medical history.
What can make the experience easier?
For an approved prescription medicine, the safest first step is following the prescriber’s escalation plan instead of changing the schedule independently.
Common practical guidance from healthcare teams may include:
- eating smaller meals;
- stopping when comfortably full;
- avoiding meals that clearly trigger symptoms;
- drinking enough fluid; and
- reporting symptoms before they become difficult to manage.
Those are general comfort ideas, not a replacement for individual medical advice.
Semaglutide medicine vs Certiva research material
This distinction should stay clear:
| Finished medicine | Certiva research reference |
|---|---|
| FDA-approved product with a prescribing label | Lyophilized laboratory reference |
| Used under healthcare supervision | For research use only |
| Side-effect rates come from human medicine trials | Batch documents describe identity and purity |
Certiva Semaglutide is not Wegovy, Ozempic, or Rybelsus. Clinical side-effect data belongs to the finished medicines and their trial programs.
For a research buyer, the commercial questions are different:
- Does the lot match the COA?
- What did HPLC measure?
- How was identity supported?
- Which vial specifications are available?
- What are the packaging, storage, lead time, and bulk options?
Certiva offers Semaglutide in 5, 10, 15, 20, 30, and 50 mg vial specifications, with 10 vials per standard box.
Separate common effects from warning signs
The most common semaglutide side effects are nausea, diarrhea, vomiting, constipation, and stomach pain—mostly during dose escalation.
The current Wegovy label gives consumers a clear pattern: digestive symptoms are the main story, nausea is the most common, and the escalation period is when reactions are reported most often.
Most participants stayed on treatment. Severe, lasting, or worrying symptoms still deserve medical attention.
Need documents for a Semaglutide research order?
If the research project requires Semaglutide, send the exact vial format, quantity, destination, and analytical documents needed for review. Certiva will respond with current-lot availability, the relevant COA, lead time, and bulk options.
View Semaglutide specifications · Read the Semaglutide vs Tirzepatide comparison · Learn how to read a peptide COA
Request the current Semaglutide COA + a quote →
Sources and further reading
- DailyMed: current Wegovy prescribing information
- DailyMed: current Ozempic prescribing information
- FDA: concerns with unapproved GLP-1 products
Frequently asked questions
What are the most common semaglutide side effects?
The most common semaglutide side effects are nausea, diarrhea, vomiting, constipation, and stomach pain—mostly during dose escalation.
How common is nausea with semaglutide?
In adult weight-management trials in the current Wegovy injection label, nausea was reported by 44% of participants receiving 2.4 mg semaglutide and 16% receiving placebo.
When are semaglutide side effects most common?
The current Wegovy label says digestive reactions were most frequently reported while the dose was being increased.
Does semaglutide cause hair loss?
Hair loss was reported by 3% of adults receiving Wegovy injection and 1% receiving placebo in the current label's weight-management trial table.
When should someone call a healthcare professional?
Contact a healthcare professional for side effects that are severe, persistent, or worrying. Urgent warning signs include severe stomach pain that does not go away, repeated vomiting or dehydration, a serious allergic reaction, yellowing of the skin or eyes, or major vision changes.
Is Certiva Semaglutide the same as Wegovy or Ozempic?
No. Certiva supplies a lyophilized semaglutide research reference for laboratory use. Wegovy and Ozempic are finished FDA-approved prescription medicines with semaglutide as the active ingredient.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →